Could a cream stop scarring hair loss? small trial begins

NCT ID NCT07487948

Recruiting now Disease control Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This pilot study tests a topical cream called delgocitinib in 30 adults with two types of scarring hair loss: lichen planopilaris and central centrifugal cicatricial alopecia. Participants apply the cream twice daily for 48 weeks. The study focuses on safety and changes in immune markers in the scalp, not yet on hair regrowth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: delgocitinib cream
What this could lead to: If successful, this could point toward a new topical treatment for scarring hair loss conditions like lichen planopilaris and central centrifugal cicatricial alopecia.
What could go wrong: This is a small, early-phase pilot study with only 30 participants, so results may not apply to everyone. The main goal is safety and biomarker changes, not yet proving the drug stops hair loss.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CENTRAL CENTRIFUGAL CICATRICIAL ALOPECIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

central centrifugal cicatricial alopecia lichen planopilaris lichen planus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CENTRAL CENTRIFUGAL CICATRICIAL ALOPECIA LICHEN PLANOPILARIS

Contacts and locations

Locations

Icahn School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.